Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0026764 (
multiple myeloma
)
36,148
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Despite the availability of therapeutic treatments,
multiple myeloma
is an incurable haematological disorder. In this study, we aimed to clarify the role of
CXorf48
as a therapeutic target in
multiple myeloma
. Based on a previously identified HLA-A*24:02-restiricted epitope from this novel cancer/testis antigen, we characterized the activities of cytotoxic T lymphocytes (CTLs) specific to this antigen against
myeloma
cells and evaluated the effects of demethylating agents in increasing antigen expression and enhancing the cytotoxic activity of CTLs.
CXorf48
expression was examined by reverse transcription polymerase chain reaction (RT-PCR) using nine
myeloma
cell lines. Cell lines with low
CXorf48
expression were treated by demethylating agents (DMAs), 5-azacytidine (5-aza), and 5-aza-2'-deoxycytidine (DAC) to evaluate gene expression using quantitative RT-PCR. Furthermore,
CXorf48
-specific CTLs were induced from peripheral blood mononuclear cells of HLA-A*24:02-positive healthy donors to evaluate antigen recognition using ELISpot and
51
Cr cytotoxicity assays.
CXorf48
was widely expressed in
myeloma
cells, and gene expression was significantly increased by DMAs. Furthermore,
CXorf48
-specific CTLs recognized DMA-treated
myeloma
cells. These findings suggest that
CXorf48
is a useful target for immunotherapy, such as vaccination, in combination with demethylating agents for the treatment of patients with
myeloma
.
...
PMID:Characteristics of a Novel Target Antigen Against Myeloma Cells for Immunotherapy. 3302 90
